Skip to content
ClinicalTrials.gov: newly registered trials· Johns Hopkins University·· 15 days agoAI score40

Psilocybin for Amblyopia - Targeting Critical Periods in Humans (PATCH)

AI summary

A newly registered trial, PATCH, will evaluate whether psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. The study will assess whether ingesting psilocybin, a naturally occurring psychoactive compound, can enhance treatment outcomes in this population.

Key facts

Compound
Psilocybin
Jurisdiction
United States
Trial registration
NCT07920081 (ClinicalTrials.gov)
Source
ClinicalTrials.gov: newly registered trials (clinicaltrials.gov)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: ClinicalTrials.gov: newly registered trials · clinicaltrials.gov

Connected to

Compound
Psilocybin
Jurisdiction
United States

Other recent items on these topics